Business Description
Solventum Corp
NAICS : 339114
SIC : 3841
ISIN : US83444M1018
Total Employee Number:
20,000Description
In spring 2024, 3M spun out its legacy healthcare segment as a stand-alone firm, Solventum. At that time, the firm comprised four segments. The smallest one—purification and filtration—has since been sold. Now, medsurg is the largest business, contributing roughly 64% of consolidated revenue, and includes advanced wound care and wound prevention. Dental solutions (restorative composites and orthodontia) and health information systems (mainly revenue cycle management) each contribute 18% of total revenue.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.08 | |||||
Equity-to-Asset | 0.34 | |||||
Debt-to-Equity | 1.1 | |||||
Debt-to-EBITDA | 2.14 | |||||
Interest Coverage | 1.98 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.2 | |||||
Beneish M-Score | -2.41 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.3 | |||||
3-Year EBITDA Growth Rate | 3.4 | |||||
3-Year EPS without NRI Growth Rate | -7.7 | |||||
3-Year Book Growth Rate | -24.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.31 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 2.17 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 69.03 | |||||
9-Day RSI | 63.39 | |||||
14-Day RSI | 61.21 | |||||
3-1 Month Momentum % | 2.41 | |||||
6-1 Month Momentum % | 10.75 | |||||
12-1 Month Momentum % | 10.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.02 | |||||
Quick Ratio | 0.74 | |||||
Cash Ratio | 0.11 | |||||
Days Inventory | 100.97 | |||||
Days Sales Outstanding | 48.21 | |||||
Days Payable | 65.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.2 | |||||
Shareholder Yield % | 20.53 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 54.7 | |||||
Operating Margin % | 6.34 | |||||
Net Margin % | 17.26 | |||||
EBITDA Margin % | 29.7 | |||||
FCF Margin % | -1.42 | |||||
OCF Margin % | 2.51 | |||||
ROE % | 30.58 | |||||
ROA % | 10 | |||||
ROIC % | 3.59 | |||||
3-Year ROIIC % | 76.43 | |||||
ROC (Joel Greenblatt) % | 136.21 | |||||
ROCE % | 17.52 | |||||
Years of Profitability over Past 10-Year | 6 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 10.95 | |||||
Forward PE Ratio | 12.03 | |||||
PE Ratio without NRI | 12.62 | |||||
PS Ratio | 1.89 | |||||
PB Ratio | 3.18 | |||||
Price-to-Operating-Cash-Flow | 74.27 | |||||
EV-to-EBIT | 10.26 | |||||
EV-to-Forward-EBIT | 26.18 | |||||
EV-to-EBITDA | 8.16 | |||||
EV-to-Forward-EBITDA | 15.27 | |||||
EV-to-Revenue | 2.42 | |||||
EV-to-Forward-Revenue | 2.49 | |||||
EV-to-FCF | -170.59 | |||||
Earnings Yield (Greenblatt) % | 9.75 | |||||
FCF Yield % | -0.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Solventum Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 7,144.686 | ||
| EPS (TTM) (€) | 6.979 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 33.29 | ||
| 14-Day RSI | 61.21 | ||
| 14-Day ATR (€) | 1.456307 | ||
| 20-Day SMA (€) | 73.87 | ||
| 12-1 Month Momentum % | 10.75 | ||
| 52-Week Range (€) | 53.6 - 77 | ||
| Shares Outstanding (Mil) | 170.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Solventum Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Solventum Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 16:30 | In 76 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 75 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 16:30 | 75.60 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 75.60 (+0.00%) | ||
| Guidance call for 2026 | 2026-06-03 09:55 | 65.20 (+2.19%) | ||
| General meeting for 2026 | 2026-05-15 09:00 | 62.80 (+0.32%) | ||
| BofA Securities Health Care Conference | 2026-05-13 10:00 | 62.00 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 16:30 | 55.80 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 55.80 (+0.00%) | ||
| Guidance call for 2026 | 2026-03-18 10:30 | 57.20 (+0.00%) |
Show
Entries
Solventum Corp Frequently Asked Questions
What is Solventum Corp(FRA:KB7)'s stock price today?
The current price of FRA:KB7 is €75.60. The 52 week high of FRA:KB7 is €77.00 and 52 week low is €53.60.
When is next earnings date of Solventum Corp(FRA:KB7)?
The next earnings date of Solventum Corp(FRA:KB7) is 2026-11-06 Est..
Does Solventum Corp(FRA:KB7) pay dividends? If so, how much?
Solventum Corp(FRA:KB7) does not pay dividend.
Press Release
Articles on Solventum Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers